| INTRODUCTION
Most of the over 200 000 prostate cancers diagnosed annually in the USA are treated by whole gland resection or ablation, a procedure accompanied by the significant side effects of impotence and incontinence. Advances in diagnostic tools, such as cancer specific biomarkers, MRI, and ultrasound (US) imaging have recently allowed for more accurate tumor grade and location, [1] [2] [3] and enabled Active Surveillance (AS) to become a clinically proven alternative to spare the prostate gland. But AS is currently limited to a small subset of patients with low risk disease, and/or the shortest life expectancy. 4, 5 The subset of patients offered AS could be broadened by application of effective adjuvant anticancer therapies. However, cancerspecific pharmaceuticals are systemically delivered, usually in multiple repeat doses that inevitably generate strong off-target toxicity. Beam radiotherapy can be locally and regionally delivered but also generates significant off-target effects in the pelvic region due to radio sensitivity of the adjacent bladder and colon, 6 and there remains no accurate method to locate and irradiate only the tumor. To eliminate or acceptably reduce offtarget effects in gland-sparing therapy, we are developing an intra-arterial drug delivery method that will use the proven clinical accessibility of the prostatic arteries and the large mass ratio of the prostate gland to the total body mass (25 g prostate vs 70 000 g body) to generate a high enough therapeutic index to enable adjuvant therapy in AS.
Arterial delivery of embolization beads is a well-documented procedure in the treatment of accessible metastases. 7 Radiolabeled embolization beads and drug-eluting embolization beads have been delivered in the setting of metastatic liver disease. 8 In prostate disease, arterial embolization has been tested successfully in hundreds of patients to relieve the symptoms of severe benign prostatic hypertrophy. 9, 10 However, no attempts have been made in either animals or humans to deliver anticancer drugs to the prostate gland by this route.
Testing therapeutic agents delivered arterially to the prostate will require a large animal model. A canine model has been developed that uses cultured Ace-1 canine prostate cancer cells implanted into prostate glands of immune-suppressed beagles. 11 We previously reported development of a novel Ace-1 cell line that was transfected with the human (hu) gastrin-releasing peptide receptor (GRPr) gene, producing a
highly GRPr expressing and biologically functioning cell line, Ace-1 huGRPr , that grows stably in culture and in nude mice. 12, 13 Nude mice xenografts were imaged with a 10 nmol intravenous dose of a GRPr-targeted optical imaging agent, IR800-G-Abz4-AMBA. 14 Herein we report the successful translation of these developments to dogs. We have developed an orthotopic canine prostate cancer model that expresses human GRPr and can be imaged with near infrared fluorescent (NIRF) optical imaging after transcatheter arterial delivery of only 50 nmol of IR800-G-Abz4-AMBA.
We believe this is the first demonstration of a human cancer growth factor receptor that has been expressed and imaged in a canine model.
| MATERIALS AND METHODS

| Ethics statement
All animal experiments were conducted according to NIH guidelines, and according to protocols approved by the Institutional Animal Care and Use Committee of The Ohio State University.
| Previously described methods
We recently published descriptions of methods used to create and maintain the Ace-1 huGRPr cell line, as well as verification of the presence, quantitative expression, and biological activity of the Ace-1 huGRPr . 15, 16 The prior work described the creation and imaging of nude mouse xenografts of this cell line and the Ace-1 parent cell line.
IR800-G-Abz4-t-BBN, a human BBN agonist, was synthesized and characterized previously. 14 We will summarize briefly selected methods used in prior work to facilitate a clear understanding of the procedures used in this study.
IR800-G-Abz4-t-BBN is soluble enough in aqueous media for the in vitro cell studies. For arterial delivery, it is formulated in 2 mL (up to 50 μM) by diluting a stock 5 mM DMSO solution 100-fold with phosphate-buffered saline (PBS).
Xenografts of Ace-1 huGRPr tumors were grown in nude mice as described. After the tumors reached 0.5-1 cm in diameter, the tumors were excised and minced with a scalpel or razor blade.
To place the catheter at the canine prostatic artery, we used X-ray fluoroscopy guided with an iodinated X-ray contrast agent, iodixanol (Visipaque 320, General Electric Healthcare, Princeton, NJ). To ensure that the highly concentrated (∼0.5 M) X-ray agent did not block the binding of IR800-G-Abz4-t-BBN to GRPr, we duplicated our previously published radioligand binding assay, but in the presence of 0-10% and a range of concentrations (0.1 nM-1 µM) of IR800-G-Abz4-t-BBN.
Binding buffers were made at 0, 1, 5, and 10 mol% iodixanol. After incubation of the binding solutions with the plated cells on ice for 1 h, the cells were washed five times with ice-cold wash buffer (25 mM HEPES, 150 mM NaCl, pH 7.4), and then lysed in 100 µL of 1 N NaOH. Solutions were then transferred to scintillation tubes and the radioactivity was measured using an automatic gamma counter (PerkinElmer Wizard II, Model 2480). The data were analyzed using GraphPad Prism 5 and reported as mean ± SE.
| Immune suppression of dogs
Orthotopic tumors in dogs were originally reported with the parent Ace-1 cell line implanted into cyclosporine immune-suppressed dogs. 11 Keller et al used oral cyclosporine to achieve trough levels of 400-600 ng/mL. In Dog 1, we attempted to repeat this procedure, implanting Ace-1 huGRPr cells into a cyclosporine (Atopica, cyclosporine A, Novartis) immune-suppressed beagle. Cyclosporine was administered (200 mg/d) and blood levels were monitored to ensure that nadir drug concentrations at 24 h after dosing were >400 ng/mL. Table 1 . Nadir blood cyclosporine concentrations (24 h after morning dosing) were 400-1200 ng/mL. 
| Optical NIRF imaging
The tissue excision procedure was monitored in real-time using a Fluobeam™ 800 NIR imaging system (Fluoptics, Grenoble, France) equipped with a 780 nm laser (7 mW/cm 2 ) for excitation and a >820 nm emission filter. Imaging was performed on excised tissues immediately after euthanization. In Dog 3 we also imaged the excised, sectioned prostate gland bearing a large tumor following storage of the tissue for 24 h in formalin to explore the effect of the formalin on the dicyanine fluorophore. Formalin fixation had little effect on the NIRF intensity. The intensity of NIRF from dissected tissues is judged to be only semi-quantitative due to signal attenuation of incident and emitted light that is characteristic of NIRF imaging. We therefore do not report quantitative data.
| Histopathology
All of the tissues discussed were obtained postmortem, imaged immediately at necropsy, and then preserved in neutral-buffered formalin. The tissues were embedded in paraffin, 4 μm sections were cut and stained with hematoxylin and eosin, and examined 2 by 2 veterinary pathologists (TJR and SME).
| RESULTS
In vitro studies. Figure 1 shows the structure of the peptide conjugate and the competition binding curves in the presence of iodixanol, the X-ray contrast agent used to guide the catheterization ( Figure 1A ). We chose iodixanol for the angiography because it is the only isotonic X-ray contrast agent that is commercially available in the high concentrations that are ideal for the fluoroscopic catheterization guidance. Our rationale was that excessive osmolality might have a significant effect on the biology of the cancer or non-cancer cells that might limit receptor expression or binding of the NIRF agent. We previously demonstrated that Ace-1 huGRPr , but diminished the apparent receptor concentration by only ∼20%.
Because these were considered acceptable suppressions, we did not attempt to ascertain the mechanism. In light of these findings we added a saline wash step after catheter placement and before administration of the 2 mL of IR800-G-Abz4-t-BBN.
| Histopathology
Observations of tumor presence or absence were confirmed in all cases by histopathology using four, H&E-stained, cross-sections of the prostate gland. 3.2 | Dog prostate imaging studies Table 1 summarizes the procedural differences among the six dogs. In Dog 1, which grew no tumors, we placed the catheter at the prostatic artery, opened the abdominal cavity under anesthesia, and imaged the | 1115 living animal as we administered the NIRF agent in aliquots. Our aim was to verify that the concentration of IR800-Abz4-t-BBN was sufficient to visualize in the prostate gland, to estimate the amount of the agent required to perfuse the gland, the volume needed and the initial kinetics.
We used a 10 nmol/mL solution in PBS, and initially delivered two 0.2 mL aliquots (4 nmol) at time 0 and 15 min later. The NIRF signal was visible by 15 min. but not immediately upon infusion (Figure 3 ). The signal was brighter at 30 min. The remaining agent was then administered in two doses 15 min apart, and images in Figure 3 were taken over the next hour with the catheter in place. Perfusion of 2 mL of the NIRF agent into arteries and veins was probably followed by slower diffusion through extracellular spaces, starting deeper within the gland, and diffusing toward the surface of the gland. Somewhat surprisingly, both lobes of the prostate were seen at roughly equal brightness, even though only the left prostatic artery was used for the administration of agent. This suggests a robust collateral circulation in the canine prostate gland. After euthanasia of Dog 1, 2 h after initial injection of the agent, the gland and local tissues were excised and imaged optically ( Figure   3E -H). No significant signal was observed in the urine and blood (not shown), muscle, and fat. The bladder was enhanced but to a lesser degree than the prostate gland. Figure 3F shows that the gland was well, but not evenly perfused, with NIRF signal considerably greater in the center of the gland, and somewhat more signal in the left lobe, the side where the catheter was placed.
For Dog 2, the more robust four-agent immune suppression protocol produced abundant tumors, with an otherwise similar than the implanted prostatic tumors, becoming larger even than the whole prostate gland, with cavernous central necrosis.
In Dog 3, we followed the same procedures as for Dog 2, but recovered the animal for 24 h before euthanasia. Figure 4 shows the images for dog 3. US ( Figure 4A ) was used to determine when tumor growth had reached 1-2 cm. The T1 THRIVE MRI was able to demonstrate extracapsular tumor enhanced with the Gd contrast agent ( Figure 4C ). The T2W TSE HR T2 image in Figure 4D showed the best separation of prostate from extensive tumor growing abundantly along the needle track from the implantation. Shadowing signal within the prostate gland in this image also indicated the presence of tumor inside the gland. Figure 5 shows the MRI and NIRF imaging results for Dog 4 (100 nmol dose of IR800-G-Abz4-t-BBN). There is a powerful NIRF signal in the sectioned excised prostate gland from the tumor ( Figure 5C ) that was clearly identified on the T2 MRI scans of the living animal prior to catheterization ( Figures 5A and 5B ). Not seen in the MRI, but extremely bright in the NIRF images was the vas deferens (partially covered by wooden tongue depressors in Figure 5C ). This signal was bright in the NIRF images prior to excision of the gland so it was followed in real time by the necropsy pathologist who located a small (<1 cm) lymph node that glowed faintly under NIRF imaging. We also tested three doses of the NIRF agent, 100, 50, and 25 nmol in Dogs 4, 5, and 6, respectively, to assess the sensitivity for detection of IR800-G-Abz4-BBN with the Fluobeam imager. Figure S1 contains Fluobeam images at different doses and exposure times demonstrating a dose effect for retention of NIRF signal. Qualitatively, we found that 50 nmol was a sufficient arterial dose for NIRF imaging of the growing tumor inside the sectioned prostate gland using the Fluobeam imager at an exposure of 150 ms.
| DISCUSSION
An effective pharmaceutical approach to expand the use of AS would preserve prostate gland function in 1000 of men who currently cannot qualify for AS due to the presence of aggressive biomarkers, tumor location, or younger age. Several gland-sparring focal ablation therapies are being explored in support of this goal, for example, thermo-and cryotherapy, photodynamic therapy, and high frequency ultrasound (HIFU). [17] [18] [19] These forms of therapy imperfectly estimate the tumor margins and would benefit from subsequent adjuvant therapy provided that it is free of serious side effects. In addition, focal therapies are unlikely to be effective in multifocal disease that is common even in intraglandular localized prostate cancer.
One therapy that is well adapted in this overall context is Peptide
Receptor Radionuclide Therapy (PRRT). 20 PRRT uses small (<2 kDa) peptides conjugated to powerful alpha and beta emitting isotopes (eg, Lu-peptide PRRT agents. 21, 22 While the off-target radiation toxicity of systemically administered PRRT agents would be too great to treat early stage prostate cancer patients, we hypothesize that the offtarget effects will be minimal to nonexistent if the agents can be effectively delivered intra-arterially to the prostate gland at a small fraction of the systemic dose. Our canine model of prostate cancer is being developed to test the hypothesis that PRRT will be useful in this therapeutic context.
We believe our study represents the first time a human cancer growth factor receptor has been expressed and grown in an experimental dog model of prostate cancer. Starting with a known isolated Ace-1 canine prostate cancer cell line that expresses very little mRNA for GRPr and does not bind GRPr targeting peptides, our prior 
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